← Back to Search

Other

Adaptive Optics System for Vision Impairment

N/A
Recruiting
Research Sponsored by Johnson & Johnson Vision Care, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be at least 18 years of age and not greater than 75 years of age at the time of consent
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2-week follow-up
Awards & highlights

Study Summary

This trial tests how light scatters in the eyes to see how age affects vision.

Who is the study for?
This trial is for people aged 18-60 with good vision (20/25 or better) and a recent eye exam. Participants must have mild to no prescription glasses (+4.00 D to -4.00 D range) and minimal astigmatism (≤1.00 D). Exclusions include pregnancy, lactation, certain diseases like diabetes or autoimmune disorders, history of ocular surgery, use of specific medications that affect the eyes, participation in another clinical trial within the last week, and employees or relatives of employees at the clinical site.Check my eligibility
What is being tested?
The study tests an Adaptive Optics System (AO) on how it measures light scatter inside the eye across different wavelengths and age groups. It's conducted at one location where participants visit four times and experience randomized sequences of testing conditions.See study design
What are the potential side effects?
Potential side effects are not explicitly listed but may include discomfort from pupil dilation agents used during testing such as proparacaine, tropicamide, phenylephrine or sodium fluorescein; allergic reactions to these substances; irritation from dental mold materials used in some procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 75 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2-week follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2-week follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Point Spread Function (PSF) for 3mm
Point Spread Function (PSF) for 4 mm
Point Spread Function (PSF) for 6 mm

Trial Design

6Treatment groups
Experimental Treatment
Group I: 900 +/- 15nm/ 830 +/- 15nm/ 770 +/- 9nmExperimental Treatment1 Intervention
Eligible subjects will be randomized to wavelength sequence 900 +/- 15nm/ 830 +/- 15nm/ 770 +/- 9nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
Group II: 900 +/- 15nm/ 770 +/- 9nm/ 830 +/- 15nmExperimental Treatment1 Intervention
Eligible subjects will be randomized to wavelength sequence 900 +/- 15nm/ 770 +/- 9nm/ 830 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
Group III: 830 +/- 15nm/ 900 +/- 15nm/ 770 +/- 9nmExperimental Treatment1 Intervention
Eligible subjects will be randomized to wavelength sequence 830 +/- 15nm/ 900 +/- 15nm/ 770 +/- 9nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
Group IV: 830 +/- 15nm/ 770 +/- 9nm/ 900 +/- 15nmExperimental Treatment1 Intervention
Eligible subjects will be randomized to wavelength sequence 830 +/- 15nm/ 770 +/- 9nm/ 900 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
Group V: 770 +/- 9nm/ 900 +/- 15nm/ 830 +/- 15nmExperimental Treatment1 Intervention
Eligible subjects will be randomized to wavelength sequence 770 +/- 9nm/ 900 +/- 15nm/ 830 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
Group VI: 770 +/- 9nm/ 830 +/- 15nm/ 900 +/- 15nmExperimental Treatment1 Intervention
Eligible subjects will be randomized to wavelength sequence 770 +/- 9nm/ 830 +/- 15nm/ 900 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.

Find a Location

Who is running the clinical trial?

Johnson & Johnson Vision Care, Inc.Lead Sponsor
216 Previous Clinical Trials
25,521 Total Patients Enrolled
Johnson & Johnson Vision Care Clinical TrialStudy DirectorJohnson & Johnson Vision Care

Media Library

Adaptive Optics System (AO) (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05602623 — N/A
Vision Impairment Research Study Groups: 900 +/- 15nm/ 830 +/- 15nm/ 770 +/- 9nm, 830 +/- 15nm/ 900 +/- 15nm/ 770 +/- 9nm, 900 +/- 15nm/ 770 +/- 9nm/ 830 +/- 15nm, 830 +/- 15nm/ 770 +/- 9nm/ 900 +/- 15nm, 770 +/- 9nm/ 830 +/- 15nm/ 900 +/- 15nm, 770 +/- 9nm/ 900 +/- 15nm/ 830 +/- 15nm
Vision Impairment Clinical Trial 2023: Adaptive Optics System (AO) Highlights & Side Effects. Trial Name: NCT05602623 — N/A
Adaptive Optics System (AO) (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05602623 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it possible for octogenarians to take part in this experiment?

"Eligibility criteria for this research requires participants to be younger than 60 years old and above the age of majority."

Answered by AI

Can I be enrolled in this research endeavor?

"The criteria for enrollment in this medical trial mandates that applicants have proper vision, ocular health and be between 18-60 years old. At the current time, up to 40 candidates are being enrolled."

Answered by AI

Is there currently an open invitation for participants to join this clinical investigation?

"According to clinicaltrials.gov, this trial is no longer recruiting patients; the recruitment process began on November 30th 2022 and finished up on the 28th of that month. Although this study has been concluded, two other trials are actively looking for participants at present."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What portion of applicants met pre-screening criteria?
Met criteria
What site did they apply to?
University of Houston College of Optometry
How many prior treatments have patients received?
1

Why did patients apply to this trial?

~19 spots leftby Dec 2024